about
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanismBroad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitutionCharacterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeatMechanism of resistance to S138A substituted enfuvirtide and its application to peptide designThe N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Potent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathwayDual-reporter phenotypic assay for human immunodeficiency virusesAmino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitorsHIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strainsDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtideEffects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats.Development and application of fluorescent SDF-1 derivatives.Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres.Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide.Identification of minimal sequence for HIV-1 fusion inhibitors.Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives.Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides.Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.Binding of multivalent anionic porphyrins to V3 loop fragments of an HIV-1 envelope and their antiviral activity.Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group.Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins.Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of alpha-helical anti-HIV peptide analogues.Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus.RNase S complex bearing arginine-rich peptide and anti-HIV activity.
P50
Q21135752-77C3D985-145E-40E9-B97E-FF5F66979A53Q24656978-27ABC90B-2555-472D-BCD2-B1AFC7442552Q27656559-101133F3-C7C1-4C07-805D-71FB4DF08143Q27661250-53B88C50-5659-4879-B0C2-FF463C218280Q34059855-46BDFEF2-6AA3-4FED-9D4E-38580B7B7394Q34352431-B6DA5A54-081F-47C8-A112-7AC5061942B5Q34385987-178B8167-B411-43AB-B731-285C884CDA10Q34779270-80F80CD5-E568-492D-BAA9-AC4CFD3C6F46Q35912640-D76668A2-6C31-48E5-9054-7BF33EC306B8Q36095908-CF493E48-82B1-4DB2-B10A-E393E693B126Q36347325-410D90E6-C087-48A4-949F-78C52B4A5167Q36424025-28F0CA16-A535-40FA-9B2F-357EF66DC655Q36452419-88153D7C-6A8E-4B20-A67B-573CBD4A291BQ36498272-7C92FE39-5091-45A5-BD3E-B5C47C6661F9Q37036508-5F4C05D6-D311-466D-94A0-CF64101D5B3FQ37099189-1FDA5EAD-C68B-41C8-A08D-3595E1DAEFB2Q37115773-DC908BDF-9A53-4863-9717-6DC8B20B13B7Q37335626-900BD2E3-EFF3-4702-BEA5-1097338094CFQ37467660-15FE034E-1629-4A75-AE98-99CE1FAECAB3Q39177353-D8283153-D68C-4DC3-B9DB-7B2CB8DAD07DQ39619500-265E9246-661A-4E25-AB8A-1A18195F7034Q39667354-9FAAC081-DA96-4F3E-AE56-4168339B7410Q39688014-441F7A3F-4702-4185-B239-1F442AB7CC4EQ39749640-0CFB8752-75A4-468F-8487-87A5D6225EF6Q39854087-C972C228-1AC9-456B-8925-EF4C597E3B53Q39935398-675D11F3-ADB9-4407-8817-EE7BB089D267Q39992049-CD8C4734-E470-4BDD-9851-0FF562AB2032Q40039248-156A99D5-7DFB-422C-85AF-5C430EFD081AQ40310128-E5A5DF72-5149-4BA4-9875-739FDF1CC8B9Q40465764-9CCF483F-A857-4AAE-ACD5-5D279D4D7621Q40544786-30F4E8E9-7614-4F2C-AB3F-AB9F5C0B534BQ42170502-A7F8AFB0-BE16-4EE9-BD8A-4802962CDE38Q43180978-B983F7ED-DB8C-4CF5-9E16-7B3FDEB91735Q43253260-00CF8FD3-FB43-40B0-AEF2-2AD83C5DE176Q43265446-9C13CBE6-6996-4227-AB7F-79E5F2ABC5EFQ43780480-9167F0C6-FCE3-47E9-AAFC-7236A19D5FCBQ45034426-225E80AD-4192-4DA1-A672-106023A16382Q45046880-75D7A1C2-F9C9-4AAE-914F-DAFC52E519BCQ45081982-5A0057D7-B771-4278-AB70-269BB996B590Q45100019-A7D47333-125A-4AE5-89F1-6B0BE31FD9AC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Eiichi Kodama
@ast
Eiichi Kodama
@en
Eiichi Kodama
@es
Eiichi Kodama
@nl
Eiichi Kodama
@sl
type
label
Eiichi Kodama
@ast
Eiichi Kodama
@en
Eiichi Kodama
@es
Eiichi Kodama
@nl
Eiichi Kodama
@sl
prefLabel
Eiichi Kodama
@ast
Eiichi Kodama
@en
Eiichi Kodama
@es
Eiichi Kodama
@nl
Eiichi Kodama
@sl
P106
P31
P496
0000-0002-6622-2752